ARWR

66.47

2.58% 1.67

Vorhandelsmarkt: 67.33 0.86 +1.29%

Arrowhead Pharmaceuticals Inc (ARWR)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt ARWR? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$64.80

Offen:

$65.6

24-Stunden-Volumen:

1.99M

Relative Volume:

0.83

Marktkapitalisierung:

$9.03B

Einnahmen:

$181.74M

Nettoeinkommen (Verlust:

$-143.97M

KGV:

-47.82

EPS:

-1.39

Netto-Cashflow:

$9.60M

1W Leistung:

-6.14%

1M Leistung:

+64.25%

6M Leistung:

+325.54%

1J Leistung:

+226.47%

1-Tages-Spanne:

$64.22

$67.30

1-Wochen-Bereich:

$59.51

$71.00

52-Wochen-Spanne:

$9.57

$72.36

Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile

Firmenname

Arrowhead Pharmaceuticals Inc

Sektor

Healthcare (1134)

Branche

Biotechnology (634)

Telefon

626-696-4702

Adresse

177 E COLORADO BLVD, PASADENA, CA

Mitarbeiter

711

Twitter

@ArrowheadPharma

Nächster Verdiensttermin

2025-11-25

Neueste SEC-Einreichungen

ARWR's Discussions on Twitter

Vergleichen Sie ARWR mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ARWR Arrowhead Pharmaceuticals Inc	66.47	8.80B	181.74M	-143.97M	9.60M	-1.39
VRTX Vertex Pharmaceuticals Inc	447.38	114.05B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	748.71	78.80B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	396.04	51.80B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	847.05	53.08B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	166.55	42.33B	447.02M	-1.18B	-906.14M	-6.1812

Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-06-05	Eingeleitet	Goldman	Neutral
2023-12-04	Eingeleitet	BofA Securities	Buy
2023-09-19	Eingeleitet	Citigroup	Neutral
2023-07-21	Eingeleitet	TD Cowen	Outperform
2023-05-12	Herabstufung	SVB Securities	Outperform → Market Perform
2023-04-26	Eingeleitet	SMBC Nikko	Outperform
2023-04-12	Hochstufung	SVB Securities	Market Perform → Outperform
2023-03-21	Eingeleitet	Bernstein	Mkt Perform
2022-09-09	Eingeleitet	Morgan Stanley	Equal-Weight
2022-05-11	Hochstufung	Robert W. Baird	Neutral → Outperform
2022-01-19	Fortgesetzt	Goldman	Buy
2021-08-06	Bestätigt	Chardan Capital Markets	Buy
2021-06-04	Fortgesetzt	Robert W. Baird	Neutral
2021-02-05	Bestätigt	H.C. Wainwright	Buy
2020-12-21	Herabstufung	Robert W. Baird	Outperform → Neutral
2020-12-16	Eingeleitet	UBS	Buy
2020-11-19	Eingeleitet	Citigroup	Buy
2020-05-13	Eingeleitet	RBC Capital Mkts	Outperform
2020-05-08	Hochstufung	Oppenheimer	Perform → Outperform
2020-04-15	Hochstufung	Cantor Fitzgerald	Neutral → Overweight
2020-03-24	Hochstufung	SVB Leerink	Underperform → Mkt Perform
2020-03-17	Eingeleitet	Goldman	Neutral
2020-01-21	Eingeleitet	SVB Leerink	Underperform
2019-12-13	Eingeleitet	Oppenheimer	Perform
2019-11-29	Bestätigt	Chardan Capital Markets	Buy
2019-11-27	Bestätigt	B. Riley FBR	Buy
2019-11-25	Hochstufung	Robert W. Baird	Neutral → Outperform
2019-10-24	Herabstufung	Robert W. Baird	Outperform → Neutral
2019-10-22	Bestätigt	Chardan Capital Markets	Buy
2019-10-03	Eingeleitet	Robert W. Baird	Outperform
2018-09-07	Hochstufung	B. Riley FBR	Neutral → Buy
2018-09-06	Bestätigt	Chardan Capital Markets	Buy
2018-08-08	Bestätigt	Cantor Fitzgerald	Overweight
2018-07-02	Bestätigt	Chardan Capital Markets	Buy

Alle ansehen

Arrowhead Pharmaceuticals Inc Aktie (ARWR) Neueste Nachrichten

07:14 AM

Will Arrowhead Pharmaceuticals Inc. stock remain a Wall Street favorite2025 Trade Ideas & AI Forecast Swing Trade Picks - DonanımHaber

07:14 AM

Dec 18, 2025

Behavioral Patterns of ARWR and Institutional Flows - news.stocktradersdaily.com

Dec 18, 2025

Trading Action: Can Arrowhead Pharmaceuticals Inc. stock attract ESG capital inflowsGap Down & Detailed Earnings Play Strategies - moha.gov.vn

Dec 18, 2025

Can Arrowhead Pharmaceuticals Inc. stock attract ESG capital inflowsJuly 2025 Movers & AI Powered Trade Plan Recommendations - Улправда

Dec 18, 2025

Dec 17, 2025

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Given New $100.00 Price Target at Piper Sandler - MarketBeat

Dec 17, 2025

Piper Sandler Raises Arrowhead Pharma (ARWR) Price Target to $100 | ARWR Stock News - GuruFocus

Dec 17, 2025

Piper Sandler raises Arrowhead Pharma stock price target to $100 on Redemplo launch - Investing.com UK

Dec 17, 2025

ARWR (Arrowhead Pharmaceuticals) 12-1 Month Momentum % : 84.44% (As of Dec. 17, 2025) - GuruFocus

Dec 17, 2025

Dec 16, 2025

Arrowhead Pharmaceuticals (NASDAQ:ARWR) CEO Christopher Richard Anzalone Sells 54,298 Shares - MarketBeat

Dec 16, 2025

Insider Selling: Arrowhead Pharmaceuticals (NASDAQ:ARWR) CEO Sells 130,000 Shares of Stock - MarketBeat

Dec 16, 2025

Arrowhead Pharmaceuticals (ARWR) Stock Drops on Dec. 16, 2025: Latest News, Analyst Forecasts, and What Investors Are Watching - ts2.tech

Dec 16, 2025

Arrowhead (ARWR) Experiences Notable Decline in Share Price - GuruFocus

Dec 16, 2025

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Down 7.6%What's Next? - MarketBeat

Dec 16, 2025

Arrowhead (ARWR) Sees Significant Decline as Stock Drops Over 12% - GuruFocus

Dec 16, 2025

Hudson Bay Capital Management LP Purchases 46,870 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat

Dec 16, 2025

Dec 15, 2025

Arrowhead Pharmaceuticals reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com

Dec 15, 2025

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Business Wire

Dec 15, 2025

36,469 Shares in Arrowhead Pharmaceuticals, Inc. $ARWR Acquired by Marex Group plc - MarketBeat

Dec 15, 2025

Dec 14, 2025

Arrowhead Pharmaceuticals (ARWR) Valuation After REDEMPLO Approval, Plozasiran Breakthrough Status and ARO-MAPT Trial Progress - Sahm

Dec 14, 2025

Dec 12, 2025

WINTON GROUP Ltd Invests $660,000 in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat

Dec 12, 2025

Arrowhead Pharma secures $200M milestone from Sarepta Therapeutics - MSN

Dec 12, 2025

Dec 11, 2025

RBC Capital Maintains Arrowhead Pharmaceuticals (ARWR) Outperform Recommendation - Nasdaq

Dec 11, 2025